La Jolla Pharmaceutical Company (LJPC:NASDAQ) Investor Relations Material

Overview

La Jolla Pharmaceutical Company is a biopharmaceutical company that specializes in the development of life-saving medicines. Its main focus is on creating therapeutics to treat severe illnesses. The company is working on two main treatments: LJPC-501, an angiotensin II potential treatment for catecholamine-resistant hypotension and hepatorenal syndrome, and GCS-100, a galectin-3 inhibitor with the potential to treat chronic kidney disease. La Jolla Pharmaceutical Company is dedicated to improving quality of life for patients worldwide.

Frequently Asked Questions

What is La Jolla Pharmaceutical Company's ticker?

La Jolla Pharmaceutical Company's ticker is LJPC

What exchange is La Jolla Pharmaceutical Company traded on?

The company's shares trade on the NASDAQ stock exchange

Where are La Jolla Pharmaceutical Company's headquarters?

They are based in San Diego, California

How many employees does La Jolla Pharmaceutical Company have?

There are 51-200 employees working at La Jolla Pharmaceutical Company

What is La Jolla Pharmaceutical Company's website?

It is http://lajollapharmaceutical.com/

What type of sector is La Jolla Pharmaceutical Company?

La Jolla Pharmaceutical Company is in the Healthcare sector

What type of industry is La Jolla Pharmaceutical Company?

La Jolla Pharmaceutical Company is in the Biotechnology industry

Who are La Jolla Pharmaceutical Company's peers and competitors?

The following five companies are La Jolla Pharmaceutical Company's industry peers:

- SkinBioTherapeutics

- Applied Genetic

- Reliv International, Inc.

- Omeros Corp

- Theravance Biopharma